RANKL,RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases |
| |
Authors: | M Baud’huin F Lamoureux L Duplomb F Rédini D Heymann |
| |
Institution: | (1) Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, EA3822, Université de Nantes, Nantes Atlantique Universités, F-44035 Nantes, France;(2) INSERM, ERI 7, F-44035 Nantes, France;(3) CHU de Nantes, F-44035 Nantes, France |
| |
Abstract: | 1997 saw the identification of a novel set of proteins within the tumor necrosis factor (TNF)/TNF receptor families that are
required for the control of bone remodeling. Therefore, these receptors, receptor activator of nuclear factor kappa B (RANK),
osteoprotegerin (OPG) and their ligand RANK ligand (RANKL) became the critical molecular triad controlling osteoclastogenesis
and pathophysiologic bone remodeling. However, the establishment of the corresponding knock-out and transgenic mice revealed
unexpected results, most particularly, the involvement of these factors in the vascular system and immunity. Thus, the OPG/RANK/RANKL
molecular triad appears to be associated with vascular calcifications and plays a pivotal function in the development of the
immune system through dendritic cells. OPG/RANK/RANKL thus constitute a molecular bridge spanning bone metabolism, vascular
biology and immunity. This review summarizes recent knowledge of OPG/RANK/RANKL interactions and activities as well as the
current evidence for their participation in osteoimmunology and vascular diseases. In fine, the targeting of the OPG/RANK/RANKL
axis as novel therapeutic approaches will be discussed.
Received 27 February 2007; accepted 4 April 2007 |
| |
Keywords: | RANKL osteoprotegerin bone remodeling osteoclast osteolysis osteoimmunology cardiovascular disease |
本文献已被 PubMed SpringerLink 等数据库收录! |
|